Kymera Therapeutics, Inc. , a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Kymera Therapeutics stock last closed at $66.86, down 3.87% from the previous day, and has increased 34.63% in one year. It has overperformed other stocks in the Biotechnology industry by 0.86 percentage points. Kymera Therapeutics stock is currently +243.84% from its 52-week low of $19.45, and -2.82% from its 52-week high of $68.80.
As of Dec 1, 2025, there are 71.95M shares of KYMR outstanding. The market value of KYMR is $4.81B. In the last 24 hours, 616,000 KYMR shares were traded.
How to Buy Kymera Therapeutics Stock
Wondering how to invest in Kymera Therapeutics stock? Here's how.
Choose where to buy Kymera Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you determine where to buy Kymera Therapeutics stock.
Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
Put funds into your brokerage account: Select your payment method and add your details.
Analyze Kymera Therapeutics stock: The Kymera Therapeutics ticker symbol is KYMR. Is Kymera Therapeutics stock a good investment? Should you buy shares of KYMR? How do KYMR's underlying business fundamentals look? Do top analysts think Kymera Therapeutics is a good buy? Why has KYMR's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if KYMR is a good stock to buy).
Execute your KYMR purchase: Decide if you will purchase KYMR shares at the current market price or use a limit order to purchase KYMR shares at a given price.
Monitor your investment in KYMR: Create a watchlist to keep track of your investment in Kymera Therapeutics stock.
Step 1: Choose where to buy Kymera Therapeutics stock
You need a brokerage account in order to access the NASDAQ market and buy KYMR shares.
A brokerage account is an investment account that enables you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. Here's why:
You can invest in stocks with zero commissions: Invest without commissions.
Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
Access to global financial markets: From Tech to Healthcare, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create a brokerage account
Now that you've chosen the right brokerage, it's time to fill out some personal details so you can invest in KYMR today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Kymera Therapeutics stock
Once you have selected the best place to buy Kymera Therapeutics stock, it's very important to research their stock prior to buying, so you truly understand the risk and opportunity.
Kymera Therapeutics Metrics
KYMR Price
$66.86
1w %
-2.68%
1y %
34.63%
5y %
23.83%
P/E
-18.57x
P/B
5.08x
P/S
133.45x
PEG
N/A
Revenue
$43.73M
Earnings
-$295.12M
Fore. Rev. Growth
5.9%
Fore. Earn. Growth
N/A
Market Cap
$4.81B
Next Earnings
N/A
Next Dividend
N/A
KYMR Fundamentals
WallStreetZen was designed to help average investors do better fundamental analysis in minutes instead of hours.
KYMR has cash burn of 230207000. It has enough cash and short-term investments to cover this for at least one year.
KYMR has $511.47M in cash and short term investments. This is enough to cover its annual cash burn of $230.21M.
KYMR has a low debt to equity ratio of 0.17.
There are more short-term assets than long-term liabilities on the KYMR balance sheet.
There are more short-term assets than short-term liabilities on the KYMR balance sheet.
Total KYMR debt is lower than 5 years ago, relative to shareholder equity.
Negative Health Checks:
KYMR profit margin has gone down from -191.3% to -674.8% in the past year.
Do analysts think it's a good time to buy Kymera Therapeutics stock
Out of 14 Equities analysts who give recommendations on KYMR, the consensus analyst rating on Kymera Therapeutics is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent KYMR Analyst Recommendations
Jeet Mukherjee, a top 32% analyst from BTIG maintains KYMR with a strong buy rating and raises their KYMR price target from $59.00 to $75.00, on Oct 22, 2025.
Joseph Catanzaro, a bottom 7% analyst from Mizuho initiates coverage on KYMR with a buy rating and announces their KYMR price target of $81.00, on Oct 21, 2025.
Geoff Meacham, a top 13% analyst from Citigroup maintains KYMR with a strong buy rating and raises their KYMR price target from $60.00 to $80.00, on Oct 17, 2025.
Citigroup's Geoff Meacham raised their price target on Kymera Therapeutics (NASDAQ: KYMR) by 33.3% from $60 to $80 on 2025/10/17. The analyst maintained their Strong Buy rating on the stock.
Kymera Therapeutics is expected to report its Q3 2025 earnings on 2025/10/29.
Meacham's price target hike was part of a Q3 2025 pre-print review of names in their Biotechnology portfolio.
According to the analyst, smaller-sized biotech stocks are starting to attract investor interest, which could bode well for the group in 2026.
Jeff Jones, a top 15% analyst from Oppenheimer maintains KYMR with a buy rating and raises their KYMR price target from $53.00 to $63.00, on Oct 1, 2025.
Brian Abrahams, a top 19% analyst from RBC Capital initiates coverage on KYMR with a buy rating and announces their KYMR price target of $70.00, on Sep 16, 2025.
Last year, KYMR revenue was $43.73M. In the last five year, KYMR's revenue has grown by 13.63% per year. This was slower than the Biotechnology industry average of 44.13%.
No, Kymera Therapeutics doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Execute your KYMR purchase
You have two main options:
Market order: A market order is an order to buy or sell a security at the best available price. Market orders are mostly fine.
Limit order: A limit order lets you buy or sell a stock at a specific price (or better). If you want to be certain you're buying or selling at a specific price, place a limit order.
Click the Open Trade button and your broker will place your order.
If you want more info about investing in stocks on eToro, click the how to video below:
How much does it cost to buy one Kymera Therapeutics share?
As of Dec 1, 2025, it costs $66.86 to buy one share of Kymera Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.15 shares of KYMR.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.